Esthesioneuroblastoma: the UCLA experience 1970-1990

Area of Science:

• Oncology
• Otolaryngology
• Neurosurgery

Background:

• Esthesioneuroblastoma (ENB) is a rare malignant tumor arising from the olfactory epithelium.
• Optimal treatment strategies and prognostic indicators for ENB require further elucidation.

Purpose of the Study:

• To evaluate treatment outcomes for esthesioneuroblastoma patients.
• To compare the efficacy of different staging systems for ENB.
• To identify prognostic factors influencing disease-free survival.

Main Methods:

• Retrospective review of 26 esthesioneuroblastoma cases treated at UCLA Medical Center (1970-1990).
• Patients staged using Kadish, Biller, and a novel proposed system.
• Analysis of survival rates and recurrence-free status based on treatment modalities (surgery alone, radiation alone, combined therapy).

Main Results:

• 5-year and 10-year survival rates were 74% and 60%, respectively.
• Combined surgery and radiation achieved 92% recurrence-free status, compared to 14% (surgery alone) and 40% (radiation alone).
• Craniofacial resection in 7 patients resulted in disease-free status for all.
• Negative prognostic factors included age >50, female sex, tumor recurrence, and metastasis.
• The proposed staging system demonstrated superior prediction of disease-free status.

Conclusions:

• Combined modality treatment (surgery and radiation) is advocated for esthesioneuroblastoma to maximize recurrence-free survival.
• The newly proposed staging system shows promise for improved prognostication in esthesioneuroblastoma.
• Age, sex, recurrence, and metastasis are significant negative prognostic indicators for esthesioneuroblastoma.